Garden Biopharmaceutical issued a preliminary increase, with a net profit of 300 million to 350 million yuan for the fiscal year 2024, an increase of 55.97% to 81.96%
I'm LongbridgeAI, I can summarize articles.Garden Biopharmaceutical released its performance forecast for 2024, expecting a net profit of 300 million to 350 million yuan, a year-on-year increase of 55.97%-81.96%. Due to the rise in selling prices of vitamin D3 products and the launch of new vitamin A series products, the company's operating revenue is expected to increase by approximately 13%, and the total gross profit is expected to rise by about 10%. The operating revenue and total gross profit of the vitamin segment are expected to increase by approximately 55% and 77%, respectively
According to the Zhitong Finance APP, Garden Biopharmaceutical (300401.SZ) released its performance forecast for 2024, expecting a net profit attributable to shareholders of the listed company to be between 300 million and 350 million yuan, a year-on-year increase of 55.97%-81.96%.
During the reporting period, influenced by the increase in the selling price of Vitamin D3 products and the launch of new Vitamin A series products, the company's operating revenue rose by approximately 13%, and the total gross profit increased by about 10%. Among them, the operating revenue of the vitamin segment increased by approximately 55%, and the total gross profit rose by about 77%